Ophthalmic Delivery of Brinzolamide by Liquid Crystalline Nanoparticles: In Vitro and In Vivo Evaluation
详细信息 查看全文
- 作者：Weijun Wu (1)
Jing Li (1)
Lin Wu (1)
Baoyan Wang (1)
Zhongyuan Wang (1)
Qunwei Xu (1)
Hongliang Xin (1) - 关键词：brinzolamide ; liquid crystalline nanoparticles ; ocular bioavailability ; ocular irritation ; ophthalmic delivery
- 刊名：AAPS PharmSciTech
- 出版年：2013
- 出版时间：September 2013
- 年：2013
- 卷：14
- 期：3
- 页码：1063-1071
- 全文大小：303KB
- 参考文献：1. Quigley H, Broman A. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-. CrossRef
2. Becher B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox: a preliminary report. Am J Ophthalmol. 1954;37:13-.
3. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt?, a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400-. CrossRef
4. Michaud J, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:235. CrossRef
5. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2000;129:136-3. CrossRef
6. Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt?) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44:S163-. CrossRef
7. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev. 1995;16:75-3. CrossRef
8. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev. 1995;16:61-3. CrossRef
9. Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, / et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm. 2005;301:121-. CrossRef
10. Han S, Shen J, Gan Y, Geng H, Zhang X, Zhu C, / et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin. 2010;31:990-. CrossRef
11. Esposito E, Cortesi R, Drechsler M, Paccamiccio L, Mariani P, Contado C, / et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res. 2005;22:2163-3. CrossRef
12. Hirlekar R, Jain S, Patel M, Garse H, Kadam V. Hexosomes: a novel drug delivery system. Curr Drug Deliv. 2010;7:28. CrossRef
13. Lopes LB, Ferreira DA, de Paula D, Garcia MTJ, Thomazini JA, Fantini MCA, / et al. Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Pharm Res. 2006;23:1332-2. CrossRef
14. Swarnakar NK, Jain V, Dubey V, Mishra D, Jain N. Enhanced oromucosal delivery of progesterone via hexosomes. Pharm Res. 2007;24:2223-0. CrossRef
15. Boyd BJ, Whittaker DV, Khoo SM, Davey G. Hexosomes formed from glycerate surfactants—formulation as a colloidal carrier for irinotecan. Int J Pharm. 2006;318:154-2. CrossRef
16. Amar-Yuli I, Wachtel E, Shoshan EB, Danino D, Aserin A, Garti N. Hexosome and hexagonal phases mediated by hydration and polymeric stabilizer. Langmuir. 2007;23:3637-5. CrossRef
17. Lee J, Kellaway IW. Buccal permeation of [D-Ala2, D-Leu5] enkephalin from liquid crystalline phases of glyceryl monooleate. Int J Pharm. 2000;195:35-. CrossRef
18. Lee J, Kellaway IW. Combined effect of oleic acid and polyethylene glycol 200 on buccal permeation of [D-Ala2, D-Leu5] enkephalin from a cubic phase of glyceryl monooleate. Int J Pharm. 2000;204:137-4. CrossRef
19. Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X, / et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm. 2010;396:179-7. CrossRef
20. H?gerstr?m H, Paulsson M, Edsman K. Evaluation of mucoadhesion for two polyelectrolyte gels in simulated physiological conditions using a rheological method. Eur J Pharm Sci. 2000;9:301-. CrossRef
21. Ye J, Wang Q, Zhou X, Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm. 2008;352:273-. CrossRef
22. Huo D, Deng S, Li L, Ji J. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Int J Pharm. 2005;289:63-. CrossRef
23. Suhonen P, Jarvinen T, Peura P, Urtti A. Permeability of pilocarpic acid diesters across albino rabbit cornea in vitro. Int J Pharm. 1991;74:221-. CrossRef
24. Liu J, Fu S, Wei N, Hou Y, Zhang X, Cui H. The effects of combined menthol and borneol on fluconazole permeation through the cornea ex vivo. Eur J Pharmacol. 2012;688:1-. CrossRef
25. Ammar HO, Salama H, Ghorab M, Mahmoud A. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10:808-9. CrossRef
26. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377-0.
27. Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine. 2010;6:318-3. CrossRef
28. Palma SD, Tartara LI, Quinteros D, Allemandi DA, Longhi MR, Granero GE. An efficient ternary complex of acetazolamide with HP-ss-CD and TEA for topical ocular administration. J Control Release. 2009;138:24-1. CrossRef
29. Seddon JM. Structure of the inverted hexagonal (H II) phase, and non-lamellar phase transitions of lipids. Biochim Biophys Acta. 1990;1031:1-9. CrossRef
30. Monduzzi M, Ljusberg-Wahren H, Larsson K. A 13C NMR study of aqueous dispersions of reversed lipid phases. Langmuir. 2000;16:7355-. CrossRef
31. Libster D, Ishai PB, Aserin A, Shoham G, Garti N. Molecular interactions in reverse hexagonal mesophase in the presence of Cyclosporin A. Int J Pharm. 2009;367(1):115-6. CrossRef
32. Barauskas J, Cervin C, Jankunec M, ?pandyreva M, Ribokait? K, Tiberg F, / et al. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes. Int J Pharm. 2010;391:284-1. CrossRef
33. Taskovich LT. Skin permeation enhancer compositions using glycerol monooleate. Google Patents. 1989.
34. Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity. Int J Pharm. 1996;142:103-3. CrossRef
35. Akman A, Cetinkaya A, Akova Y, Ertan A. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye. 2004;19:145-1. CrossRef
36. Boyd BJ, Whittaker DV, Khoo SM, Davey G. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int J Pharm. 2006;309:218-6. CrossRef - 作者单位：Weijun Wu (1)
Jing Li (1)
Lin Wu (1)
Baoyan Wang (1)
Zhongyuan Wang (1)
Qunwei Xu (1)
Hongliang Xin (1)
1. School of Pharmacy, Nanjing Medical University, Lane 818, East Tianyuan Road, Nanjing, Jiangsu, 211166, People’s Republic of China
文摘
Brinzolamide (BLZ) is a drug used to treat glaucoma; however, its use is restricted due to some unwanted adverse events. The goal of this study was to develop BLZ-loaded liquid crystalline nanoparticles (BLZ LCNPs) and to figure out the possibility of LCNPs as a new therapeutic system for glaucoma. BLZ LCNPs were produced by a modified emulsification method and their physicochemical aspects were estimated. In vitro release study revealed BLZ LCNPs displayed to some extent prolonged drug release behavior in contrast to that of BLZ commercial product (Azopt?). The ex vivo apparent permeability coefficient of BLZ LCNP systems demonstrated a 3.47-fold increase compared with that of Azopt?. The pharmacodynamics was checked over by calculating the percentage fall in intraocular pressure and the pharmacodynamic test showed that BLZ LCNPs had better therapeutic potential than Azopt?. Furthermore, the in vivo ophthalmic irritation was evaluated by Draize test. In conclusion, BLZ LCNPs would be a promising delivery system used for the treatment of glaucoma, with advantages such as lower doses but maintaining the effectiveness, better ocular bioavailability, and patient compliance compared with Azopt?.